BioMarin Pharmaceutical | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
Acadia Pharmaceuticals USD 123.66M 2.71M 2025-06
Agios Pharmaceuticals USD 45.87M 4.34M 2025-06
Alnylam Pharmaceuticals USD 323.31M 83.36M 2025-06
Amgen USD 1.69B 4M 2025-06
Bayer EUR 3.55B 162M 2025-06
Biogen USD 583.8M 11.3M 2025-06
BioMarin Pharmaceutical USD 232.28M 26.16M 2025-06
Gilead Sciences USD 1.36B 100M 2025-06
Incyte USD 331.02M 5.33M 2025-06
Insmed USD 76.44M 71.11M 2025-06
Ionis Pharmaceuticals USD 90.6M 14.6M 2025-06
Moderna USD 230M 18M 2025-06
Neurocrine Biosciences USD 286.3M 9.8M 2025-06
PTC Therapeutics USD 85.26M 76.66M 2025-06
Regeneron Pharmaceuticals USD 634.2M 1.2M 2025-06
Roche Holding CHF 3.61B 381M 2024-12
Sanofi EUR 1.24B 1.44B 2024-12
Sarepta Therapeutics USD 69.89M 63.74M 2025-06
Ultragenyx Pharmaceutical USD 86.65M 1.15M 2025-06
United Therapeutics USD 212.5M 42.4M 2025-06
Vertex Pharmaceuticals USD 424.6M 28.2M 2025-06


BioMarin Pharmaceutical Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.